Risk for rheumatoid arthritis reduced for patients with T2DM
(HealthDay)—Patients with type 2 diabetes mellitus (T2DM) have a reduced risk for rheumatoid arthritis (RA), which may be due to […]
THURSDAY, Oct. 15, 2020 — Ertugliflozin is noninferior to placebo with respect to major adverse cardiovascular events among patients with […] MONDAY, Nov. 26, 2018 — From 2018 to 2030, the insulin required to treat type 2 diabetes is expected to […] THURSDAY, Nov. 1, 2018 — Intensive blood pressure (BP) control and fenofibrate use in patients with type 2 diabetes who […]T2DM
Ertugliflozin Noninferior for CV Outcomes in T2DM With ASCVD
Insulin Needed for T2DM Tx Set to Increase >20 Percent by 2030
ASN: Aggressive Control of BP, Lipids in T2DM May Up Kidney Risk